It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely die from the ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Support grows for a new test designed to monitor individuals at risk of multiple myeloma, aiming for earlier detection and ...

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the ...

Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM).

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The ...